Agentix (AGTX) Gains from Investment Securities (2016 - 2017)
Agentix's (AGTX) quarterly Gains from Investment Securities came in at $10164.0 in Q3 2017, down 75.2% YoY from $40986.0 in Q3 2016, and down 66.66% on a QoQ basis from $30489.0 in Q2 2017.
Agentix (AGTX) Gains from Investment Securities (2016 - 2017) Analysis & Trends
Agentix (AGTX) has 2 years of Gains from Investment Securities data on file, last reported at $10164.0 in Q3 2017.
- Quarterly Gains from Investment Securities fell 75.2% year-over-year to $10164.0 in Q3 2017, while the trailing twelve-month figure through Aug 2017 was $173462.0 (changed N/A YoY) and the FY2017 annual result came in at $173462.0, down 17.95% from the prior year.
- Gains from Investment Securities declined to $10164.0 in Q3 2017, from $30489.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $80660.0 in Q1 2017 to a low of $10164.0 in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Agentix | 801,339.00 | 801,301.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Aug 31, 2017 | 10,164.00 |
| Aug 31, 2017 | 10,164.00 |
| May 31, 2017 | 30,489.00 |
| May 31, 2017 | 30,489.00 |
| Feb 28, 2017 | 80,660.00 |
| Feb 28, 2017 | 80,660.00 |
| Nov 30, 2016 | 52,149.00 |
| Nov 30, 2016 | 52,149.00 |
| Aug 31, 2016 | 40,986.00 |
| Aug 31, 2016 | 40,986.00 |